The FDA announced that it has approved generic version of Plavix (clopidogrel), a blood thinner indicated to reduce the risk of heart attack and stroke in patients who have had a recent heart attack or a recent stroke, or have partial or total blockage of an artery (peripheral artery disease).
Clopidogrel works by decreasing the platelet formation.
The following companies are now able to market the 300 mg generic version of Plavix: Dr. Reddy's Laboratories, Gate Pharmaceuticals, Mylan Pharmaceuticals, and Teva Pharmaceuticals.
Apotex Corporation, Aurobindo Pharma, Mylan Pharmaceuticals, Roxane Laboratories, Sun Pharma, Teva Pharmaceuticals and Torrent Pharmaceuticals are now able to market the 75 mg clopidogrel.
Apotex Corporation,
Clopidogrel works by decreasing the platelet formation.
The following companies are now able to market the 300 mg generic version of Plavix: Dr. Reddy's Laboratories, Gate Pharmaceuticals, Mylan Pharmaceuticals, and Teva Pharmaceuticals.
Apotex Corporation, Aurobindo Pharma, Mylan Pharmaceuticals, Roxane Laboratories, Sun Pharma, Teva Pharmaceuticals and Torrent Pharmaceuticals are now able to market the 75 mg clopidogrel.
Apotex Corporation,
No comments:
Post a Comment